81514-40-1

Usage

Uses

Used in Medicinal Chemistry:
9-Benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one is utilized as a key intermediate in the synthesis of novel pharmaceutical compounds due to its unique structural features and reactivity, which facilitate the creation of diverse molecular structures with potential therapeutic applications.
Used in Drug Development:
In the pharmaceutical industry, 9-Benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one serves as a valuable building block for the development of new drugs. Its distinct properties allow for the design of molecules with specific biological activities, making it instrumental in advancing drug discovery and innovation.
Used in Organic Synthesis:
9-Benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one is employed as a versatile component in organic synthesis, where its functional groups and structural attributes enable the formation of complex molecular architectures with potential applications in various chemical and biological fields.
Used in Chemical Research:
As a subject of interest in chemical research, 9-Benzyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-one is used to explore new reaction pathways, mechanisms, and the synthesis of complex organic molecules, contributing to the advancement of chemical knowledge and technology.

Upstream product

• 542-05-2 acetonedicarboxylic acid 
• 7456-83-9 2,2'-oxybis(acetaldehyde) 
• 100-46-9 benzylamine 
• 56999-16-7 2-(2,2-diethoxyethoxy)-1,1-diethoxyethane 
• 1558-67-4 formic anhydride 
• 1085458-56-5 2-(2,2-diethoxyethoxy)-1,1-dimethoxyethane 
• 3287-99-8 benzylamine hydrochloride 
• 1126795-00-3 3-oxa-9-azabicyclo[3.3.1]nonan-7-one hydrochloride 
• 100-39-0 benzyl bromide 
• 502-50-1 4-Ketopimelic acid 
• 4358-64-9 cis-1,4-anhydroerythritol 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 285-69-8 3,4-epoxytetrahydrofuran 

Downstream Products

• 141380-03-2 N-benzyl-7-oxa-9-azabicyclo<3.3.1>nonane-3-carbonitrile 
• 141380-04-3 ethyl N-benzyl-7-oxa-9-azabicyclo<3.3.1>nonane-3-carboxylate 
• 141380-12-3 6-(diphenylmethyl)octahydro-4,8-methanopyrido<2,1-c><1,4>oxazin-7-one 
• 926658-87-9 3-oxa-9-azabicyclo[3.3.1]nonan-7-one 
• 1085458-59-8 10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decan-4-one 
• 1085458-61-2 tert-butyl 10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decane-3-carboxylate 
• 1085458-68-9 tert-butyl 10-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-8-oxa-3,10-diazabicyclo[4.3.1]decane-3-carboxylate 
• 1085458-32-7 3-(6-fluoroquinazolin-2-yl)-10-[2-(2H-1,2,3-triazol-2-yl)benzoyl]-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 1085458-63-4 10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 1085458-73-6 (1R,6S)-10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 1085458-75-8 (1S,6R)-10-benzyl-8-oxa-3,10-diazabicyclo[4.3.1]decane 
• 1085458-70-3 C₁₆H₁₉N₅O₂ 

Relevant academic research and scientific papers

SUBSTITUENT-INCLUDING UREA COMPOUND

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)

THERAPEUTICALLY ACTIVE BICYCLIC-SULPHONAMIDES AND PHARMACEUTICAL COMPOSITIONS

Pharmaceutical compounds have a bicyclic-sulphonamide structure and pharmaceutical compositions including the compounds may be used in therapy as brain-cell-death protectants and may be used, for example, in the treatment of chronic neurodegenerative diseases. The compounds are active as inhibitors of N-acylethanolamine-hydrolysing acid amidase (NAAA) and may be used for the therapeutic treatment and prevention of pain and inflammatory disorders and other disorders which benefit from the modulation of fatty acid ethanolamides, particularly palmitoylethanolamide (PEA).

SUBSTITUTED BRIDGED DIAZEPANE DERIVATIVES AND USE THEREOF

The present application relates to novel imidazopyridinyl-or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

3-OXA-8-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AND THIER USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2;R N is H or Me; R1 is optionally one or more halo or methyl groups;R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH2 OH; R 2c and R 2d (if present) are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and(iv) CH 2 OH;R 3a and R 3b are independently selected from H and Me; R 4a is selected from OH,-NH 2, -C(=O)NH 2, and -CH 2 OH; R 4b is either H or Me; R5 is either H or Me; m is 1 or 2; q is 0 or 1;R 11a, R 11b, R 11c and R 11d are independently selected from H, halo, C1-4 alkyl, C 1-4 fluoroalkyl, C 3-4 cycloalkyl, C 1-4 alkyloxy, NH-C 1-4 alkyl and cyano; R 12a and R 12b are independently selected from the group consisting of: (i) F; (ii) H;(iii) Me; and (iv) CH 2 OH; R 12c and R 12d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH 2 OH;R 12e is H or Me; R 13a and R 13b are independently selected from H and Me; R 14 is either H or Me; R 16a and R 16b are independently selected from H and Me; R 6 is selected from H, OMe, and OEt.

6-BRIDGED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula: wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as or pharmaceutically acceptable salts, or tautomerism isomers, or enantiomers, or diastereomers thereof. The invention also contains compositions including the compounds and methods of using the compounds for the treatment or prophylaxis of hepatitis B virus infection.

6-SUBSTITUTED BENZOXAZINES

The present invention is concerned with 6-substituted benzoxazine derivatives of formula (I) wherein X, Y, R1 and R2 are as described herein, their manufacture, and pharmaceutical compositions containing them. The active compounds of the present invention are 5-HT5A receptor antagonists, useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders, Parkinson's disease, psychiatric disorders or gastrointestinal disorders.

PYRIMIDINE DERIVATIVES AS GPCR MODTTLATORS FOR USE IN THE TREATMENT OF OBESITY AND DIABETES

The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic di

N-Bridged bicyclic sulfonamides as inhibitors of γ-secretase

The structural modification of a series of [3.3.1] bicyclic sulfonamide based γ-secretase inhibitors is described. Appropriate substitution on the bicyclic scaffold provides a significant increase in the metabolic stability of the compounds resulting in an improved in vivo metabolic profile.

SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF

The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administeri

OXO BRIDGED DIAZEPAN OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to oxo bridged diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.